# CTX310 one-year data show ANGPTL3, LDL and triglyceride cuts last

Canonical page: https://technooptimist.io/stories/ctx310-one-year-data-show-angptl3-ldl-and-triglyceride-cuts-last-44a66d87
Date: 28 Aug 2026
About: [CRISPR Therapeutics](https://technooptimist.io/companies/crispr-therapeutics.md) · [CTX310 (ANGPTL3)](https://technooptimist.io/biotech/ctx310.md)
Original source: https://www.hcplive.com/view/ctx310-gene-editing-sustains-angptl3-ldl-cuts-1-year

CRISPR Therapeutics reported one-year follow-up for CTX310, its one-time gene-editing therapy against ANGPTL3, at ESC 2026 and in the New England Journal of Medicine. The reductions from a single infusion held for a year in the highest-dose group, with no new serious treatment-related side effects.

## Key facts

- The phase 1a trial enrolled 15 adults at five dose levels in Australia and New Zealand; the one-year data cover the highest dose (0.8 mg/kg) in 4 participants.
- At one year in that group, ANGPTL3 fell a mean of 78.6%, LDL cholesterol 52.5% and triglycerides 47.8%.
- Three participants had grade 2 infusion reactions that resolved; one had a transient liver enzyme rise soon after dosing with no ongoing liver problems.
- A phase 1b trial is testing a fixed 0.8 mg/kg dose in patients with refractory dyslipidemias, with a severe hypertriglyceridemia cohort update expected in the second half of 2026.

---

The Techno Optimist tracks every frontier of technology, program by program: https://technooptimist.io/ (a Markdown version of any page: add .md to its URL; site map for agents: https://technooptimist.io/llms.txt).
Data API (JSON, realtime stream): https://technooptimist.io/developers. People read 5 pages free, then Reader $10/month; these Markdown pages are open to agents.